Evolus (EOLS) announced that it has submitted the final module of its premarket approval application to the FDA for Evolysse Sculpt, an injectable hyaluronic acid gel product designed to restore mid-face volume. Evolus anticipates that the FDA’s review will follow the standard PMA process, with approval expected in the second half of 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EOLS:
- Evolus, Inc. Advances Safety Study of NUCEIVA for Glabellar Lines
- Evolus, Inc. Faces Financial Instability Amid Economic Uncertainty and Consumer Spending Risks
- Evolus, Inc. Earnings Call: Mixed Sentiments and Strategic Goals
- Evolus: Strategic Growth and Cost Optimization Support Buy Rating Amid Market Challenges
- Disney reports Q3 beat and NFL deal, Uber authorizes $20B buyback: Morning Buzz